ABVC BioPharma Receives $240,000 Licensing Payment from OncoX BioPharma, Total Payments Reach $2.53 Million

ABVC BioPharma has received a US$240,000 licensing payment from OncoX BioPharma, bringing the total licensing payments to approximately US$2.53 million. This includes US$935,950 in licensing payments from OncoX in 2025 and US$1.15 million in total from OncoX since the inception of their collaboration. The licensing agreement covers four oncology product candidates targeting myelodysplastic syndrome, triple negative breast cancer, pancreatic cancer, and non-small cell lung cancer.